Glibaheal M

Product Overview

Glibaheal M is a combination oral anti-diabetic medication containing Glibenclamide and Metformin as active ingredients. This dual-action formulation is specifically designed for managing type 2 diabetes mellitus. Glibenclamide, a sulfonylurea derivative, stimulates pancreatic insulin secretion, while Metformin, a biguanide, enhances insulin sensitivity and reduces hepatic glucose production. Their synergistic action provides comprehensive blood sugar control for diabetic patients.

Therapeutic Indications

This medication is indicated for adult patients with type 2 diabetes mellitus when monotherapy with either Glibenclamide or Metformin, along with lifestyle modifications, proves insufficient for adequate glycemic control. It effectively addresses hyperglycemia through dual mechanisms: augmenting insulin release while simultaneously decreasing glucose production and improving peripheral glucose uptake.

Administration Guidelines

For optimal results and minimal gastrointestinal discomfort:
• Take tablets with meals
• Swallow whole with water (do not crush or chew)
• Begin with low doses, gradually titrating based on glycemic response
• Maintain prescribed dietary and exercise regimens
• Regular blood glucose monitoring is essential

Mechanism of Action

The medication operates through complementary pharmacological actions:
1. Glibenclamide component: Binds to pancreatic β-cell sulfonylurea receptors, stimulating insulin secretion
2. Metformin component:
– Inhibits hepatic gluconeogenesis
– Enhances peripheral insulin sensitivity
– Improves glucose utilization in muscle tissue
This dual approach addresses multiple pathophysiological aspects of type 2 diabetes.

Dosage Protocol

Standard dosing recommendations:
• Initial regimen: 1 tablet once or twice daily with meals
• Maximum daily dose: Typically 2 tablets twice daily
• Dose adjustments should be:
– Based on regular glucose monitoring
– Gradual (over weeks)
– Supervised by healthcare providers
Note: Renal function should be assessed before and during treatment.

Therapeutic Advantages

1. Comprehensive glycemic control through dual mechanisms
2. Addresses both fasting and postprandial hyperglycemia
3. Convenient dosing schedule enhances compliance
4. Potential reduction in diabetes-related complications
5. May delay disease progression when used appropriately

Adverse Effects

Most frequently observed reactions include:
• Hypoglycemic episodes (especially with Glibenclamide component)
• Gastrointestinal symptoms (primarily Metformin-related):
– Nausea
– Diarrhea
– Abdominal discomfort
• Rare but serious considerations:
– Lactic acidosis (with Metformin)
– Hepatic enzyme alterations
– Hypersensitivity reactions

Precautions and Contraindications

Important safety considerations:
▲ Absolute contraindications:
– Type 1 diabetes
– Diabetic ketoacidosis
– Severe renal/hepatic impairment
– History of lactic acidosis
▲ Requires caution in:
– Elderly patients
– Those with cardiovascular disease
– Patients undergoing radiocontrast procedures
– Alcohol users
Regular monitoring of renal function and blood glucose is mandatory.

Storage Conditions

To maintain product stability:
• Store at controlled room temperature (20-25°C)
• Protect from moisture and light (keep in original packaging)
• Avoid bathroom or kitchen storage
• Keep securely out of children’s reach
• Do not use if packaging is compromised

Medical Disclaimer

The information provided herein is intended for educational purposes only and represents current medical knowledge at the time of publication. This content:
• Is not exhaustive regarding all possible effects or interactions
• Should not replace professional medical advice
• Requires individual assessment by qualified practitioners
Patients should always consult their healthcare providers regarding:
✓ Appropriate treatment options
✓ Potential drug interactions
✓ Management of adverse effects
✓ Ongoing monitoring requirements
This information aims to facilitate informed patient-provider discussions, not to substitute clinical judgment.